Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board: Benjeddou, Mongi / Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.


CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.277
Source Normalized Impact per Paper (SNIP) 2018: 0.446

Online
ISSN
2363-8915
See all formats and pricing
More options …
Volume 32, Issue 3

Issues

Imatinib quantification in human serum with LC-MS3 as an effective way of protein kinase inhibitor analysis in biological matrices

Marek Dziadosz
  • Corresponding author
  • Institute of Legal Medicine, Hannover Medical School (MHH), Carl-Neuberg-Str. 1, 30625 Hannover, Germany, Phone: +495115324558, E-mail:
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Michael Klintschar / Jörg Teske
Published Online: 2017-08-08 | DOI: https://doi.org/10.1515/dmpt-2017-0016

Abstract

Background:

As imatinib gained a lot of attention in the field of medicine, appropriate methods are needed for drug analysis. LC-MS/MS combined with complex sample preparation and column enrichment is usually the method of choice when high sensitivity is necessary. The application of LC-MS3 in imatinib quantification has not been discussed in the literature.

Methods:

An LC-MS3 imatinib quantification method was developed and validated in human serum. The sample preparation was based on the liquid-liquid extraction of 50 μL human serum. Chromatographic separation was performed using a Luna 5 μm C18 (2) 100 A, 150 mm×2 mm column and the elution was done using a mobile phase consisting of A (H2O/methanol=95/5, v/v) and B (H2O/methanol=3/97, v/v), both with 10 mM ammonium acetate and 0.1% acetic acid.

Results:

The conditions applied resulted in a limit of detection/quantification value of 0.14/0.45 ng/mL reached without a sophisticated sample preparation technique or enrichment column application. It could be demonstrated that MS3 detection is a very effective way of sensitive imatinib quantification. Further, it could be stated that the strategy presented can be very useful for a sensitive analysis of other protein kinase inhibitors, because their molecule structure is appropriate for MS3 detection.

Conclusions:

The presented analytical strategy is an effective way of protein kinase inhibitor analysis in human serum.

Keywords: Gleevec; Glivec; imatinib; liquid chromatography-tandem mass spectrometry; STI-571; tyrosine kinase inhibitor

References

  • 1.

    Baselt RC. Disposition of toxic drugs and chemicals in men, 9th ed. Seal Beach: Biomedical Publications, 2011.Google Scholar

  • 2.

    Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ. Sample methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Biomed Chromatogr 2013;27:335–42.PubMedGoogle Scholar

  • 3.

    Caterino M, Casadei GM, Arvonio R, De Francia S, Pirro E, Piccione FM, et al. Quantification of imatinib plasma levels in patients with chronic myeloid leukemia: comparison between HPLC-UV and LC-MS/MS. Int Pept Res Ther 2013;19:109–16.Web of ScienceCrossrefGoogle Scholar

  • 4.

    Miura M, Takahashi N, Sawada K. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J Chromatogr Sci 2011;49:412–5.CrossrefPubMedGoogle Scholar

  • 5.

    Dziadosz M, Bartels H. Imatinib quantification in human serum for clinical purposes using high performance liquid chromatography with diode array detector. Acta Chim Slov 2011;58:347–50.PubMedGoogle Scholar

  • 6.

    Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B 2004;804:431–4.CrossrefGoogle Scholar

  • 7.

    Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, et al. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B 2004;803:285–92.CrossrefGoogle Scholar

  • 8.

    Guetens G, Prenen H, De Boeck G, van Oosterom A, Schöffski P, Highley M, et al. Simultaneous determination of AMN107 and imatinib (Gleevec®, Glivec®, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. J Chromatogr B 2007;846:341–5.Web of ScienceCrossrefGoogle Scholar

  • 9.

    Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, et al. Liquid chromatographic method for detection and quantification of STI–571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J Chromatogr B 2004;799:23–36.CrossrefGoogle Scholar

  • 10.

    Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011;412:1060–7.Web of SciencePubMedCrossrefGoogle Scholar

  • 11.

    Götze L, Hegele A, Metzelder SK, Renz H, Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta 2012;413:143–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 12.

    Zhang Y, Qiang S, Yu Z, Zhang W, Xu Z, Yang L, et al. LC-MS/MS determination of imatinib and N-desmethyl imatinib in human plasma. J Chromatogr Sci 2014;52:344–50.CrossrefWeb of ScienceGoogle Scholar

  • 13.

    Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuno A. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human serum. Biomed Chromatogr 2013;27:502–8.CrossrefGoogle Scholar

  • 14.

    Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed Chromatogr 2009;23:1251–8.CrossrefWeb of SciencePubMedGoogle Scholar

  • 15.

    Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002;768:325–40.CrossrefGoogle Scholar

  • 16.

    Andriamanana I, Gana I, Duretz B, Hulin A. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B 2013;926: 83–91.CrossrefWeb of ScienceGoogle Scholar

  • 17.

    Dziadosz M, Lessig R, Bartels H. HPLC-DAD protein kinase inhibitor analysis in human serum. J Chromatogr B 2012; 893–894:77–81.Web of ScienceGoogle Scholar

  • 18.

    Dziadosz M, Lessig R, Bartels H. Protein kinase inhibitor analysis with the core-shell separation technique. Anal Bioanal Chem 2012;404:2083–6.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 19.

    Dziadosz M, Wagner MC, Lipka DB, Fischer T, Bartels H. High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard. J Liq Chrom Rel Technol 2012;35:2503–10.Google Scholar

  • 20.

    Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019–30.CrossrefPubMedGoogle Scholar

About the article

Received: 2017-04-10

Accepted: 2017-07-13

Published Online: 2017-08-08

Published in Print: 2017-09-26


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Drug Metabolism and Personalized Therapy, Volume 32, Issue 3, Pages 147–150, ISSN (Online) 2363-8915, ISSN (Print) 2363-8907, DOI: https://doi.org/10.1515/dmpt-2017-0016.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in